Autonomic drugs in ophthalmology: Some problems and promises. Section IV: Sympatholytic and sympathetic blocking agents--alpha adrenergic antagonists and beta adrenergic antagonists.
D018663:Adrenergic Agents / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D003986:Dibenzocycloheptenes / Q000494:pharmacology / Q000627:therapeutic use; D004357:Drug Synergism; D004837:Epinephrine / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy; D006145:Guanethidine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology / Q000627:therapeutic use; D007429:Intraocular Pressure / Q000187:drug effects*; D013948:Moxisylyte / Q000494:pharmacology; D011217:Practolol / Q000627:therapeutic use; D011433:Propranolol / Q000009:adverse effects / Q000494:pharmacology; D011437:Propylamines / Q000494:pharmacology
D018663:Adrenergic Agents; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D003986:Dibenzocycloheptenes; D006892:Hydroxydopamines; D011437:Propylamines; D011433:Propranolol; D013948:Moxisylyte; D011217:Practolol; D004837:Epinephrine; D006145:Guanethidine